Aripiprazole and haloperidol: Beneficial combination antipsychotic therapy for a schizophrenic patient

Clinical Neuropharmacology

Volumn 31, Issue 3, 2008, Pages 173-175

  Kuo, Joseph ^a   Hwu, Hai Gwo ^b  

^a Lotung St Mary's Hospital   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Aripiprazole; Haloperidol; Partial agonist; Schizophrenia

Indexed keywords

ARIPIPRAZOLE; HALOPERIDOL; OLANZAPINE;

ABSENCE OF SIDE EFFECTS; ADULT; ANAMNESIS; ARTICLE; CASE REPORT; CLINICAL FEATURE; COMBINATION CHEMOTHERAPY; DIAGNOSTIC PROCEDURE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG RESPONSE; DRUG WITHDRAWAL; HUMAN; MALE; MONOTHERAPY; PRIORITY JOURNAL; RIGIDITY; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; TREATMENT OUTCOME;

ADULT; ANTIPSYCHOTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; HALLUCINATIONS; HALOPERIDOL; HUMANS; MALE; PIPERAZINES; PROLACTIN; QUINOLONES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME;

EID: 44649141976     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/WNF.0b013e318123ee01     Document Type: Article

References (12)

1. Casey DE, Carson WH, Saha AR, et al. Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study. Psychopharmacology (Berl) 2003;166:391-399.
2. Lieberman JA. Dopamine partial agonists: a new class of antipsychotic. CNS Drugs 2004;18:251-267.
3. DeLeon A, Patel NC, Crismon ML. Aripiprazole: a comprehensive review of its pharmacology, clinical efficacy, and tolerability. Clin Ther 2004;26:649-666.
4. Kane JM, Carson WH, Saha AR, et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 2002;63:763-771.
5. Potkin SG, Saha AR, Kukawa MJ, et al. Aripiprazole, an anti-psychotic with a novel mechanism of action, and risperidone vs. placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 2003;60:681-690.
6. Travis MJ, Burns T, Dursun S, et al. Aripiprazole in schizophrenia: consensus guidelines. Int J Clin Pract 2005;59:485-495.
7. Burris KD, Molski TF, Ryan E, et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 2002;302:381-389.
8. Grunder G, Carlsson A, Wong DF. Mechanism of new antipsychotic medications. Arch Gen Psychiatry 2003;60:974-977.
9. Benkert O, Grunder G, Wetzel H. Dopamine autoreceptor agonists in the treatment of schizophrenia and major depression. Pharmacopsychiatry 1992;25:254-260.
10. Tamminga CA. Partial dopamine agonists in the treatment of psychosis. J Neural Transm 2002;109:411-420.
11. Burke MJ, Lincoln J. Aripiprazole and haloperidol: a clinically relevant interaction with a dopamine antagonist and partial agonist. Ann Clin Psychiatry 2006;18:129-130.
12. Reeves RR, Mack JE. Worsening schizoaffective disorder with aripiprazole. Am J Psychiatry 2004;161:1308.